2016
Current Therapies for the Medical Management of Diabetes
Inzucchi SE, Majumdar SK. Current Therapies for the Medical Management of Diabetes. Obstetrics And Gynecology 2016, 127: 780-794. PMID: 26959197, DOI: 10.1097/aog.0000000000001332.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsClinical Decision-MakingDecision MakingDiabetes Mellitus, Type 2HumansHypoglycemic Agents
2014
Glycemic Targets What is the Evidence?
Inzucchi S, Majumdar S. Glycemic Targets What is the Evidence? Medical Clinics Of North America 2014, 99: 47-67. PMID: 25456643, DOI: 10.1016/j.mcna.2014.08.018.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsComplications of diabetesGlucose hypothesisStrong epidemiologic associationGlycemic targetsDiabetes mellitusGlucose loweringMetabolic abnormalitiesMajor trialsEpidemiologic associationGlucose levelsClinical practiceHyperglycemiaEpidemiologic relationshipComplicationsDiabetesMellitusAbnormalitiesDiagnosisTrials
2013
Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?
Majumdar SK, Inzucchi SE. Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy? Endocrine 2013, 44: 47-58. PMID: 23354728, DOI: 10.1007/s12020-013-9884-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetesGlucose loweringCurrent therapiesFree Fatty Acid Receptor AgonistsNewer incretin-based therapiesGlucose cotransporter 2 inhibitorsDurable glycemic controlCotransporter 2 inhibitorsIncretin-based therapiesType 2 diabetes therapyIndividual patient characteristicsAcid receptor agonistsNew therapeutic classDiverse patient populationsMechanism of actionInsulin useComplex regimensPatient characteristicsGlycemic controlPatient populationType 1 inhibitorNatural courseReceptor agonistClinical trialsTreatment choice